Abstract

Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome

Author(s): Riepl Mike

Issue: Nov/Dec 2018 - Volume 22, Number 6

Page(s): 456-465

Download in electronic PDF format for $75
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 1
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 2
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 3
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 4
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 5
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 6
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 7
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 8
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 9
  • Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 10

Abstract

Homeostasis of the human vaginal microbiome, which consists of the bacteriome (colonizing bacteria) and the mycobiome (resident fungi), is essential to the health of the female reproductive system. Dysbiosis of either microbial community can be caused by a variety of factors ranging from behavioral issues (personal-hygiene practices, the choice of contraceptives, smoking, etc.) to biological variables (the host-microbiome composition, menstruation, the robustness of the host’s immune response). Clinicians often consult compounding pharmacistsbabout the formulation and use of customized preparations to treat vaginal diseases and re-establish a healthful vaginal microenvironment when commercially manufactured products have failed or are unavailable. In this article, the function of the human vaginal bacteriome and mycobiome are examined, a common microorganism identified in each of those microenvironments is discussed, factors that cause dysbiosis are reviewed, and the role of biofilm in the vaginal microbiota is explored. A question typical of those asked by prescribers committed to improving women’s health and decreasing the incidence of recurring bacterial vaginosis or fungal infections is answered. Formulations for compounds that help ensure or reestablish the homeostasis of the human vaginal bacteriome and mycobiome are also provided.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2018
Pg. 456-465
Author(s): Riepl Mike
Nov/Dec 2009
Pg. 556
Author(s): Allen Loyd V Jr
Jul/Aug 2009
Pg. 338
Author(s): Allen Loyd V Jr
Sep/Oct 2008
Pg. 450
Author(s): Allen Loyd V Jr
Jul/Aug 2016
Pg. 322
Author(s): Allen Loyd V Jr
Jan/Feb 2024
Pg. 58
Author(s): Allen Loyd V Jr
May/Jun 2018
Pg. 196-202
Nov/Dec 2018
Pg. 504-511
Jul/Aug 2009
Pg. 334
Author(s): Allen Loyd V Jr
Nov/Dec 2003
Pg. 469
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 77-81
May/Jun 2004
Pg. 181-185
May/Jun 2004
Pg. 185
Jan/Feb 2004
Pg. 52
Author(s): Allen Loyd V Jr
Sep/Oct 2001
Pg. 375
Author(s): Allen Loyd V Jr
Nov/Dec 1998
Pg. 436
Author(s): Allen Loyd V Jr
Nov/Dec 2000
Pg. 460
Author(s): Allen Loyd V Jr
Nov/Dec 2000
Pg. 464
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 48
Author(s): Allen Loyd V Jr
Jan/Feb 1998
Pg. 50
Author(s): Allen Loyd V Jr